PubMed Health⌕ Search

Biomedical subjects

T N Aleksandrovskaia

Publications and source records attributed to T N Aleksandrovskaia.

At least 19 recordsLinked to original sources
PubMed2005

[The features of uric acid metabolism in women in climacterium].

The purpose of the study was to establish the prevalence of uric acid (UA) metabolism disturbances as a possible risk factor of urate nephropathy in women of various age groups. The authors carried out a retrospective analysis of 757 case histories and performed uricemia and uricosuria screening in women aged 18 to 69 years. The study revealed significant age-dependent elevation of uricemia, with hyperuricemia (HUE) at the age of 60 to 69 years old. The study also found age-dependent increase of HUE rate with its significant elevation in postmenopausal women (older than 50 years), compared with HUE rate in reproductive age women (18 to 49 years old) -37.9% vs. 11.4%. For the first time the researchers established UA excretion level and found a significant tendency of uricosuria to decrease with age (p < 0.016 between the groups of 40 to 49 and 50 to 59 years old). The highest rate of hyperuricosuria was revealed in women of 40 to 49 years old (22.2%), while in women of 18 to 29 and 60 to 69 years old it was 10.1% to 12.1%. For the first time the authors established the rate of hypouricosuria in women, which culminated in women older than 50 (22% of cases). The increase of HUE rate, which is most prominent in postmenopausal women, is associated with the decrease in UA excretion, accompanied by the decrease of hyperuricosuria rate and increase of hypouricosuria rate. Taking into account high prevalence of UA metabolism disturbances in women older than 50, menopause may be considered a risk factor of HUE and urate nephropathy.

Adolescent↗
PubMed1994

[Gemfibrozil in the treatment of lipid metabolism disorders].

The study was made of gemfibrozil tolerance and effectivity against atherosclerosis and in correction of lipid metabolism in 20 patients with hyperlipidemia. (11 males and 9 females, a mean age 51 +/- 3.1 years). The assessment of the treatment efficacy was performed clinically, biochemically, using bicycle ergometry exercise. Eight weeks of gemfibrozil treatment in a dose 12-1.8 g/day produced a hypolipidemic effect in 90% of the patients which were mostly of IIb and IV genotypes. The highest efficacy was reported in lowering triglycerides, VLDL cholesterol. In less extent the drug reduced LDL cholesterol. Some of the patients became hypolipidemic by HDL cholesterol. It is concluded that in hyperlipidemic patients gemfibrozil improves the running of atherosclerosis without the effect on angina pectoris.

Adult↗
PubMed1991

[The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].

There were 56 patients with hyperlipoproteinemias, treated with lipantil in a dose of 300-600 mg/day. After 8 weeks of the treatment the blood triglyceride content declined by 65.4%, the blood content of total cholesterol 24.1%, that of low density lipoprotein cholesterol 21.1%, of very low density lipoprotein cholesterol 34.1%; the content of high density lipoprotein cholesterol rose by 28.0%. The drug also exerted a uricosuric action. The rate of side effects was 3.6%.

Arteriosclerosis↗
PubMed1990

[The clinico-morphological characteristics of psoriatic nephropathy].

Based on studying the data obtained during examination of patients with psoriasis combined with the urinary syndrome possible varieties of psoriatic nephropathy, namely chronic glomerulonephritis (CGN) and amyloidosis were distinguished. CGN combined with psoriasis was mainly represented by latent glomerulonephritis (GN) and morphologically, it was mostly represented by the mesangio-proliferative variant, with IgA and C3 being fixed on the basal membrane of the capillaries and in the mesangium. The clinicomorphological feature of that form of psoriatic GN is combination of the signs of both associated CGN and hyperuricemia and IgA-nephritis. Special emphasis is laid on the diagnosis of rapid-progressing GN which is of paramount importance for institution of early etiopathogenetic therapy. Amyloidosis associated with psoriasis is characterized by the signs of acquired disease (AA-amyloidosis) and does not differ in its course from amyloidosis coupled with other diseases.

Adolescent↗
PubMed1989

[Clinical evaluation of the Glucophot reflecting photometer in determining glucose in whole blood].

Clinical trials of the Glukofot reflecting photometer prototype for measuring the whole blood glucose in reagent strips have been carried out. The reproducibility has been assessed in various operations with different glucose concentrations. Attempts to estimate the calibration curve linearity and the accuracy with the control sera as against the glucose oxidase method have failed, probably because of the presence of stabilizers and inhibitors, and different viscosity of these substances as compared to whole blood viscosity. The rapid method has been compared to the universal methods and the neocuproin method for glucose measurements with the use of the AA autoanalyzer; the results obtained with these methods have coincided. The apparatus failures and approaches to improving its operation are discussed; it appears to be useful for blood glucose analysis in emergencies, at bedside, in ambulance cars, etc.

Adult↗
PubMed1988

[Isolation and immunoenzyme determination of human beta 2-microglobulin].

Two procedures for isolation of homogeneous beta 2-microglobulin from urine of patients with systemic lupus erythematosus were developed: a procedure for isolation of beta 2-microglobulin with two-stage gel chromatography on Sephacryl S-200 and a procedure for isolation of homogeneous beta 2-microglobulin with affinity chromatography on rabbit polyclonal antibodies. The microglobulins isolated with the two procedures showed identical physicochemical properties and were used in development of a competitive immunoenzymatic assay method for determination of beta 2-microglobulin in the blood. The method was approved for determination of beta 2-microglobulin in blood serum of patients.

Animals↗
PubMed1988

[New mechanisms of a positive effect of curantyl in chronic nephritis].

The effects of curantyl (dipiridamole) on the excretion of prostaglandins E2 and F2 alpha (PGF2 alpha and PGF2 alpha) and renal hemodynamics (RHD) were studied in patients with hypertensive nephritis in an acute test and during prolonged (up to 21 mos) single-agent therapy. In the acute test curantyl increased PG excretion in 15 out of 18 patients by 86.8 +/- 17.6%, mainly at the expense of PGE2 (133.2 +/- 33.1%), and renal blood flow in 11 out of 12 patients by 32.1 +/- 7.7%. During prolonged therapy curantyl also raised PGE2 excretion and improved RHD (raised renal blood flow, glomerular filtration and decreased renal vascular resistance). Besides, during prolonged single-agent therapy curantyl reduced renin plasma activity, increased circulating blood volume, insignificantly reduced BP, and possessed an antiproteinuric and antihematuric effect. It is concluded that curantyl can stimulate PG renal biosynthesis improving RHD in hypertensive nephritis that can have a beneficial effect on a course of this disease.

Adult↗
PubMed1988

[Disorders of purine metabolism as an etiological factor in renal pathology].

Of 3200 patients admitted to the nephrology department within several years, hyperuricemia was detected in 696. Excluding from this number persons with signs of chronic renal insufficiency (146 persons) and patients who were treated by diuretics (89), the frequency of hyperuricemia was 16.2% which exceeded almost 2-fold (9.2%) the value determined during the examination of 594 healthy persons. The authors discussed a possibility of early development of renal pathology in purine metabolic derangement with hyperuricosuric and hyperuricemic stages characterized by certain clinical peculiarities, including a possibility of development of immune complex nephritis.

Arthritis, Gouty↗